Melissa K Frey

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. Frey M, Sandler G, Sobolev R, Kim S, Chambers R, Bassett R, et al. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes. Gynecol Oncol. 2017;146:123-128 pubmed publisher
  2. Frey M, Ellis A, Koontz L, Shyne S, Klingenberg B, Fields J, et al. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum. Gynecol Oncol. 2017;146:386-391 pubmed publisher
    ..Physicians and survivors must carefully consider treatment toxicities and quality of life effects when selecting drugs for patients with incurable disease. ..
  3. Schwartz Z, Frey M, Philips S, Curtin J. Endometrial cancer surveillance adherence reduces utilization and subsequent costs. Gynecol Oncol. 2017;146:514-518 pubmed publisher
    ..This reduction does not appear to affect patient outcomes and led to an appreciable decrease in surveillance costs. ..
  4. Frey M, Dao F, Olvera N, Konner J, Dickler M, Levine D. Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol. 2017;147:621-625 pubmed publisher
    ..Serious side effects include hypertension, proteinuria, bowel perforation, and thrombosis. We tested the hypothesis that genetic variation in hypertension-associated genes is associated with bevacizumab-induced hypertension (BIH)...